<DOC>
	<DOCNO>NCT02567175</DOCNO>
	<brief_summary>FDA currently allow patient 12 year age older various gastrointestinal ( GI ) condition treat Domperidone Expanded Access Investigational Drugs program . These condition include gastroesophageal reflux disease upper GI symptom , gastroparesis , chronic constipation . Patients must fail standard therapy eligible receive Domperidone . This program facilitate availability investigational drug , ( Domperidone ) patient serious disease condition comparable satisfactory alternative therapy diagnose , monitor , treat patient 's disease condition .</brief_summary>
	<brief_title>Domperidone Expanded Access Protocol Patients With Gastrointestinal Disorders</brief_title>
	<detailed_description>Expanded Access Program Design : The purpose Expanded Access Program provide oral Domperidone patient ' â‰¥12 year age , accord investigator 's judgment , prokinetic effect need relief refractory gastroesophageal reflux disease upper gastrointestinal ( GI ) symptom , gastroparesis , chronic constipation . The objective Expanded Access Program allow use Domperidone patient gastrointestinal disorder fail standard therapy . Failed standard therapy constitute follow treatment : PPI Therapy , Erythromycin , allergy medication . Subject must therapy time period 1 month consider ineffective .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Domperidone</mesh_term>
	<criteria>1 . Male female 2 . Age 12 old 3 . Symptoms manifestation secondary GERD ( e.g. , persistent esophagitis , heartburn , upper airway sign symptom respiratory symptom ) , gastrointestinal motility disorder nausea , vomit , severe dyspepsia severe chronic constipation refractory standard therapy . Failed standard therapy constitute follow treatment : PPI Therapy , Erythromycin , allergy medication . Subject must therapy time period 1 month consider ineffective . 4 . Patients must comprehensive evaluation eliminate cause symptom . 5 . Patient Parent/Legal Guardian sign informed consent child assent ( appropriate ) administration Domperidone inform patient potential adverse event include : increase prolactin level extrapyramidal side effect breast change cardiac arrhythmia include QT prolongation death There potential increase risk adverse event drug list Domperidone protocol addendum ( see Appendix ) . 6 . Patients weight &gt; 35kg 7 . Patients able swallow Domperidone pill . 1 . History , current , arrhythmias include ventricular tachycardia , ventricular fibrillation Torsade des Pointes . Patients minor form ectopy ( PACs ) necessarily exclude . 2 . Clinically significant bradycardia , sinus node dysfunction , heart block . Prolonged QTc ( QTc &gt; 450 millisecond male , QTc &gt; 470 millisecond female ) . 3 . Hepatic dysfunction 4 . Renal insufficiency 5 . Clinically significant electrolyte disorder . 6 . Gastrointestinal hemorrhage obstruction 7 . Presence prolactinoma ( prolactinreleasing pituitary tumor ) . 8 . Pregnant breast feed female 9 . Known allergy Domperidone 10 . The use medication interact Domperidone . . Subjects may require stop use ( washout ) medication interact Domperidone . If subject willing able stop use interact medication , may exclude withdrawn study investigator 's discretion . Based medication subject may require stopuse wash , PI determine appropriate washout period use clinical judgment . Some medication may require much long washout period others , explain respective subject require stop medication .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>